Neuren Pharmaceuticals Limited Overview
Neuren Pharmaceuticals is a New Zealand-incorporated, Melbourne-headquartered biopharmaceutical company that discovers and develops orally administered synthetic analogues of naturally occurring peptides derived from insulin-like growth factor 1 (IGF-1), targeting serious neurodevelopmental disorders of early childhood. Its first drug, trofinetide, is the only approved therapy for Rett syndrome in the US, EU, Canada and Israel. Acadia Pharmaceuticals markets it under an exclusive worldwide licence as DAYBUE®, DAYBUE® STIX and, in the EU, DAYBU®. In return Neuren receives tiered royalties and milestones, which converted the company from a cash-consuming developer into a profitable, debt-free royalty business with A$287m of cash. That cash flow now funds the company's second asset, NNZ-2591 (ercanetide), which is in the first-ever Phase 3 trial in Phelan-McDermid syndrome and in development for Pitt Hopkins syndrome, Angelman syndrome and hypoxic-ischemic encephalopathy. In 2026 Neuren introduced a semi-annual, fully franked dividend, which makes it a rare dividend-paying ASX biotech.
Company's own description
In its 2026 ASX announcements, Neuren describes itself as "developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options," with therapies that "target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides" (About Neuren boilerplate, H1 2026 announcement, 26 Aug 2026).
Independent characterisation
Neuren is best understood as a hybrid royalty vehicle and clinical-stage developer. It has two economic engines.
-
Trofinetide royalty and milestone stream (out-licensed, commercial). Neuren does not manufacture, sell or distribute trofinetide. Acadia holds an exclusive worldwide licence: North America since 2018, extended to the rest of the world in 2023. Acadia funds all development, regulatory, manufacturing and commercial activity. Neuren's economics consist of:
-
North America: tiered, escalating double-digit royalties on net sales. The first tier is 10%, which was the effective rate in 2023 according to the Q4 2023 Activity Report. Sales milestones are payable when calendar-year North American net sales cross escalating thresholds. The first, US$50m at the US$250m threshold, was earned in FY2024. The next is US$50m when North American net sales exceed US$500m in a calendar year (H1 2026 announcement).
-
Europe: US$35m on first commercial sale, up to US$170m of sales milestones, and tiered royalties from mid-teens to low-20s percent of European net sales (H1 2026 announcement).
-
Japan: US$15m on first commercial sale for Rett, US$4m on first commercial sale for a second indication, up to US$110m of sales milestones, and mid-teens to low-20s percent royalties (H1 2026 announcement; 24 Apr 2024 announcement).
-
Other ex-North America territories: royalties and milestones under the 2023 global licence expansion, on terms summarised in Neuren's licence disclosures.
-
Fragile X: a further US$55m milestone if Acadia develops trofinetide for Fragile X syndrome (Q4 2023 Activity Report).
-
-
NNZ-2591 (ercanetide) development (wholly owned, clinical). Neuren keeps worldwide rights to NNZ-2591 in all indications except Rett syndrome and Fragile X syndrome, which are licensed to Acadia. Neuren funds and runs NNZ-2591 development itself. It is the main source of the company's long-term optionality, including potential Rare Pediatric Disease Priority Review Vouchers (PRVs), which Neuren would own 100% of.
Revenue model mix
| Revenue type | Nature | FY2025 status |
|---|---|---|
| Royalties | Recurring, quarterly, US$-denominated, tied to DAYBUE net sales | A$64.6m. This is about 76% of total revenue from ordinary activities (derived from the FY2025 Appendix 4E). |
| Milestones (development, first sale, sales thresholds) | Episodic, large, US$-denominated | Nil in FY2025. A$80.5m in FY2024; A$59.4m in FY2023. |
| Upfront licence fees | One-off | A$146m in FY2023 (global licence expansion) |
| PRV proceeds share | One-off | A$76.5m in FY2024 (Neuren's one-third share of Acadia's PRV sale) |
| Finance income | Interest on cash and term deposits | A$5.6m in H1 2026 |
| Product sales / services / subscriptions | — | Not applicable |
Value-chain position, customers and end-markets
Value-chain position: Upstream. Neuren covers discovery, early and late clinical development (for NNZ-2591), regulatory strategy and IP ownership. For trofinetide it sits entirely upstream of its licensee's commercial operations.
Customer: Effectively one, Acadia Pharmaceuticals (Nasdaq: ACAD), which is the sole source of royalty and milestone revenue. End users are patients with Rett syndrome and their prescribing physicians, accessed through Acadia.
End-markets: Rare paediatric neurodevelopmental disorders: Rett syndrome (commercial), Phelan-McDermid syndrome (Phase 3), Pitt Hopkins syndrome (end of Phase 2), Angelman syndrome (Phase 2 completed), and hypoxic-ischemic encephalopathy (pre-IND). Fragile X syndrome is licensed to Acadia.
Strategy
Stated strategy
Neuren's strategy has three pillars, set out consistently since 2024 ("three key drivers adding value", ASX 24 Apr 2024):
-
Realise Neuren's share of trofinetide value in the US through royalties and sales milestones.
-
Realise Neuren's share of trofinetide value outside North America through the Acadia global licence (Europe, Japan and other markets).
-
Maximise the value of NNZ-2591 as a multiple-indication platform, with global rights kept by Neuren.
In 2026 management added a fourth explicit theme: optimising total shareholder return through ongoing fully franked dividends, while funding all NNZ-2591 development internally. The CEO described this as the "enviable position" of funding development "aiming for significant capital appreciation, as well as optimis[ing] total shareholder return" (H1 2026 announcement).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Koala Phase 3 (PMS) | Initiated 2025; first dosing Feb 2026 | First-ever Phase 3 in PMS; about 160 children; US$80–90m program budget |
| PTHS regulatory path | Early 2026 to Oct 2026 | Alternative trial designs and endpoint methodologies assessed; Type B meeting with FDA in late Oct 2026 |
| HIE program | Added H1 2025 | Pre-IND engagement Feb 2026; juvenile animal study; IND expected H1 2027 |
| SYNGAP1 program | Added 2025 | Early stage |
| Capital management: buybacks | Dec 2024 to H1 2026 | A$50m program completed H1 2025 (average A$12.27); further on-market buybacks of A$3.9m in H1 2026 |
| Dividend policy | Aug 2026 | Semi-annual payout of 70–100% of the Available Pool, fully franked to the maximum extent possible |
| Community and diagnosis initiatives | 2025–2026 | Presenting Sponsor of the PMSF Family Conference (Jul 2026); supported a prevalence study in Autism Research estimating PMS at 1 in 7,300 |
| PRV optionality | Ongoing | US PRV program reauthorised to Sep 2029. Neuren holds Rare Pediatric Disease designations in PMS, PTHS and AS and would own 100% of any voucher. A recent industry sale was US$215m (Jul 2026). |
ESG and cost programs: No formal ESG targets or cost-reduction programs are disclosed. Corporate costs are deliberately small (A$6.2m in FY2025; A$6.6m estimated for FY2026).
Guidance
| Item | Guidance | Source |
|---|---|---|
| FY2026 royalty income | US$52.6–56.2m (rounded US$53–56m), about A$75.1–80.3m at 0.70. Originally A$70–77m (Feb 2026). | H1 2026 announcement |
| FY2026 Available Pool | A$48.0–51.6m | H1 2026 announcement |
| FY2026 corporate & admin costs | About A$6.6m | H1 2026 announcement |
| PMS program total cost | US$80–90m | H1 2026 announcement |
| Acadia FY2026 DAYBUE net sales | US$480–510m | Acadia, Aug 2026 |
| Acadia 2028 DAYBUE target | US$700m global net sales | Acadia, reaffirmed Aug 2026 |
| Japan | Top-line Sep–Nov 2026; submission 2027 | 5 Aug 2026 announcement |
Neuren does not give medium-term revenue or EPS targets of its own.
Products & Services
Commercial product (out-licensed)
| Attribute | Trofinetide: DAYBUE® oral solution |
|---|---|
| Molecule | Trofinetide (formerly NNZ-2566), a synthetic analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1 |
| Indication | Rett syndrome. US: adults and paediatric patients aged 2 and over. |
| Approvals | US FDA (Mar 2023); Health Canada; Israel; European Commission (24 Aug 2026, as DAYBU, ages 5 and over) |
| Launch | US, 17 Apr 2023 (Acadia). Germany anticipated early Q4 2026. |
| Commercialiser | Acadia Pharmaceuticals (exclusive worldwide licence) |
| Net sales (Acadia, US$) | 2023: 177.2m; 2024: 348.4m; 2025: 391.4m; H1 2026: 226m (global) |
| 2026 guidance | US$480–510m global net sales (raised from US$460–490m in Aug 2026) |
| Long-term target | Acadia reaffirmed a target of US$700m global net sales in 2028 |
| Neuren economics | Tiered North American royalty starting at 10%; North American sales milestones; ex-North America royalties of mid-teens to low-20s percent; Europe and Japan milestones (see Section 2.2) |
| Pricing | Set by Acadia; not disclosed by Neuren |
| Attribute | Trofinetide: DAYBUE® STIX |
| Description | New powder (sachet) formulation of trofinetide, designed to improve ease of administration and tolerability management |
| Launch | Limited US launch in Q1 2026 at Rett syndrome Centers of Excellence (over 250 prescriptions, about 30% for new or returning patients); broad US availability from early Q2 2026 |
| Adoption | By 30 Jun 2026, 40% of US DAYBUE patients were on STIX. About 45% of STIX demand in Q2 2026 came from new or returning patients. |
| Significance | Acadia credits STIX for the record Q2 2026 net sales of US$125m (+30% YoY) and the guidance upgrade |
| Attribute | Trofinetide: DAYBU® (EU) |
| Approval | European Commission, 24 Aug 2026, for neurobehavioural symptoms of Rett syndrome in adults and children aged 5 and over |
| Coverage | All 27 EU member states plus Iceland, Liechtenstein and Norway |
| Path | Negative CHMP trend vote (Feb 2026), then negative opinion (Mar 2026), then re-examination, then positive opinion (Jun 2026), then EC approval |
| Next Neuren payment | US$35m on first commercial sale. Germany launch expected early Q4 2026. No launch announcement had been located by 12 Oct 2026. |
| Attribute | Trofinetide: Japan program |
| Status | Acadia-run clinical trial. Top-line results are expected Sep–Nov 2026. A regulatory submission under Orphan Drug designation is anticipated in 2027. |
| Next Neuren payment | US$15m on first commercial sale |
Clinical pipeline: NNZ-2591 (ercanetide), wholly owned by Neuren (ex-Rett and Fragile X)
| Program | Stage | Key data / status | Designations | Source |
|---|---|---|---|---|
| Phelan-McDermid syndrome (PMS) | Phase 3 ("Koala") | Randomised, double-blind, placebo-controlled; about 160 children aged 3–12; 13-week treatment plus 52-week open-label extension. First participant dosed Feb 2026. Sites grew from 2 to 15 (US and Canada) during 2026. Over 100 families referred. 8 extension-study sites active. Program cost guided at US$80–90m. Formal top-line timing guidance to come after further enrolment milestones. | Orphan Drug (US, EU), Fast Track, Rare Pediatric Disease | H1 2026 announcement |
| Pitt Hopkins syndrome (PTHS) | End of Phase 2 | Positive Phase 2 (May 2024). FDA's written feedback in early 2026 suggested a design similar to the PMS trial; Neuren considered that "not appropriate or executable" given PTHS rarity. A Type B End of Phase 2 face-to-face meeting with FDA is scheduled for late Oct 2026. An externally-led patient-focused drug development meeting is scheduled for 13 Nov 2026. | Orphan Drug (US, EU), Fast Track, Rare Pediatric Disease | H1 2026 announcement |
| Angelman syndrome (AS) | Phase 2 completed | Positive Phase 2 (Aug 2024): clinician-rated CGI-I mean 3.0 (11 of 13 children improved, p=0.0010); caregiver-rated CIC mean 3.2 (p=0.0273). Neuren has signalled priority for PMS and PTHS, where competition is lower. | Orphan Drug (US, EU), Fast Track, Rare Pediatric Disease | ASX 9 Aug 2024; Angelman.org |
| Hypoxic-ischemic encephalopathy (HIE) | Pre-IND | FDA generally accepted the proposed IND-opening study and doses (Feb 2026) but requested an additional juvenile animal safety study. Neuren submitted the protocol in May 2026 but has not received feedback. IND now expected H1 2027 (previously Q4 2026). | — | H1 2026 announcement |
| Prader-Willi syndrome (PWS) | Open IND (2024) | Neuren held an open US IND in 2024. It is not named in the H1 2026 pipeline description, and current status was not clarified in sources reviewed. | — | ASX 9 Aug 2024 |
| SYNGAP1-related disorder (SRD) | Early / preclinical | Added to the pipeline in 2025 (FY2025 results). It is not named in the H1 2026 pipeline description, and current status was not clarified in sources reviewed. | — | FY2025 Appendix 4E |
| Rett and Fragile X (NNZ-2591) | Licensed to Acadia | Acadia holds worldwide rights; development status not disclosed by Neuren | — | Neuren company description |
Financial Narrative
Income statement
Sources: FY2025 Appendix 4E; FY2024 results; FY2023 results (FNArena, Biotech Daily); FY2021–FY2023 line items from Yahoo Finance (financial statements data). FY2024 R&D and corporate costs are derived from the FY2025 Appendix 4E, which reports FY2025 R&D up A$3.4m to A$36.4m and corporate costs up A$1.5m to A$6.2m. FY2025 PBT is derived as NPAT plus tax; the company rounds it to A$39m.
EPS discrepancy: FNArena reports FY2023 EPS as A$1.236, while Biotech Daily reports A$1.2016. This likely reflects a basic versus diluted difference and is noted rather than resolved.
EBITDA: depreciation and amortisation are immaterial (net PP&E was A$31k at FY2024). EBITDA therefore approximates operating income but is not reported by the company and is left blank.
Margins (derived)
Revenue CAGR. FY2022–FY2025 three-year CAGR is about 80% (derived: 14.55 to 84.8). A five-year CAGR is not meaningful because FY2021 revenue was nil. Royalty income CAGR for FY2023–FY2025 is about 55% (derived: 26.8 to 64.6). The FY2023 base covers only about 8.5 months of sales.
Balance sheet
Sources: Moomoo/Yahoo balance-sheet data for FY2020–FY2024 cash and receivables; FY2025 Appendix 4E for FY2025 cash; FinancialFilings summary of the FY2025 Annual Report for total assets and equity. Goodwill is shown as nil because no acquisitions have been made; this is not separately confirmed from the notes.
The FY2024 receivables spike (A$157.6m) reflects Q4 2024 PRV proceeds, the sales milestone and Q4 royalty, all received in Q1 2025. Pro-forma cash at 31 Dec 2024 after these receipts and Q4 tax was A$359.4m (FY2024 results).
H1 2026 balance sheet: cash and short-term investments of A$287m; total assets of A$340.6m; no debt (H1 2026 Appendix 4D).
Working capital: Almost the entire asset base is cash, term deposits and receivables against about A$4.4m of total liabilities (FY2025). Working capital is therefore roughly equal to net assets, about A$338m (derived).
Cash flow
Sources: Q4 2023 Activity Report ("cash generated from operations ... full-year A$185 million"); FY2025 results (OCF A$125m versus A$11m used in 2024; tax payments A$54m in 2025); FY2025 Appendix 4E and H1 2025 announcement for buybacks. Capex is immaterial (PP&E is in the tens of thousands of dollars) and is shown as nil.
FY2024's negative operating cash flow is a timing effect: most FY2024 income was earned in Q4 and collected in Q1 2025.
H1 2026: buybacks of A$3.9m. First interim dividend of A$19.0m declared, paid 7 Oct 2026, so it falls in H2 2026 cash flow.
Commentary on trends, inflections and drivers
FY2021–FY2022: pre-commercial developer. Neuren lost A$7.8m in FY2021 and spent about A$9.5m on R&D, mainly the NNZ-2591 Phase 1 program and drug manufacture (H1 2022 Appendix 4D). FY2022 brought the first licence-related revenue (A$14.55m) and a small profit (A$0.18m). Cash rose only slightly to A$40.2m.
FY2023: transformation year. FDA approval and the US launch triggered three income streams at once: royalties (A$26.8m at a 10% first-tier rate), the first-commercial-sale milestone (A$59.4m), and the upfront payment for the global licence expansion (about A$146m). Revenue rose roughly 16-fold to A$231.9m. Net profit was A$157.1m after A$48.1m of tax, and cash rose more than five-fold to A$228.5m without dilution.
FY2024: record income with a shift in mix. Royalties more than doubled to A$56.2m as DAYBUE net sales grew 97% to US$348.4m. Revenue also included the first sales milestone (A$80.5m) and Neuren's share of PRV proceeds (A$76.5m). The A$7.2m net FX loss was offset by A$24m of FX translation gains in other comprehensive income. Recognition of previously unrecognised New Zealand tax losses (about A$17m) reduced tax expense. Neuren started buying back shares.
FY2025: normalisation to a royalty-only base. With no milestones, revenue fell 63% to A$84.8m and net profit fell 79% to A$30.4m. Recurring royalty income still grew 15% to A$64.6m. R&D rose to A$36.4m as Koala began. Operating cash flow was A$125m because FY2024 receivables were collected, and cash rose to A$296.1m despite A$39.6m of buybacks and A$54m of tax payments.
H1 2026: investment phase plus capital return. Royalty income rose 29% in US$ terms, but R&D almost doubled to A$27.4m, and net profit fell to A$4.9m. With royalties growing and R&D funded from the cash pile, Neuren introduced a dividend of 70–100% of the after-tax "Available Pool", defined as royalty income less corporate costs, after tax at 30%. This deliberately separates shareholder distributions from R&D spending.
Structural features to note:
-
Revenue is US$-denominated while reporting is in A$. FX moves create translation gains and losses: an A$8.0m gain in FY2025 and an A$4.0m gain in H1 2026.
-
The company pays Australian/NZ corporate tax, which generates franking credits for dividends.
-
Profitability now depends on the pace of NNZ-2591 R&D rather than on revenue. As the Phase 3 program scales, reported profit could fall further even as royalties grow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue Lines
| Revenue line (AUD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Royalty income (DAYBUE) | 0 | 0 | 26.8 | 56.2 | 64.6 |
First commercial sale milestone | 0 | 0 | 59.4 | 0 | 0 |
Sales milestone (US$250m threshold) | 0 | 0 | 0 | 80.5 | 0 |
Upfront licence fee (global expansion) | 0 | 0 | 145.7 | 0 | 0 |
Share of PRV sale proceeds | 0 | 0 | 0 | 76.5 | 0 |
Licence or milestone revenue (pre-launch) | — | 14.55 | 0 | 0 | 0 |
Other revenue incl. finance income (derived residual) | — | — | 0 | 14.6 | 20.2 |
Total revenue from ordinary activities | 0 | 14.55 | 231.9 | 227.8 | 84.8 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Royalty share of total revenue (%) | 0 | 11.6 | 24.7 | 76.2 |
Royalty YoY growth, A$ (%) | — | — | 109.7 | 15.0 |
Total revenue YoY growth (%) | — | 1,494 | -1.8 | -62.8 |
Pre-tax margin (%) | 1.3 | 88.4 | 80.3 | 46.0 |
Results by Segment and Revenue by Segment
| Metric | H1 2025 | H1 2026 | Change |
|---|---|---|---|
Royalty income (USD Mn) | 18.1 | 23.3 | +29% |
Royalty income (AUD Mn) | 28.3 | 33.2 | +17% |
Revenue from ordinary activities (AUD Mn) | 39.5 | 42.7 | +8% |
R&D expense (AUD Mn) | 14.9 | 27.4 | +A$12.5m |
Corporate & administration (AUD Mn) | — | 3.0 | — |
Finance (interest) income (AUD Mn) | — | 5.6 | — |
FX gain (AUD Mn) | — | 4.0 | — |
Profit before tax (AUD Mn) | 19.7 | — | — |
Profit after tax (AUD Mn) | 15.0 | 4.9 | -67% |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue from ordinary activities (AUD Mn) | 0 | 14.55 | 231.9 | 227.8 | 84.8 |
Royalty income (AUD Mn) | 0 | 0 | 26.8 | 56.2 | 64.6 |
Gross profit (AUD Mn; no cost of sales) | 0 | 14.55 | 231.9 | — | — |
R&D expense (AUD Mn) | 9.5 | 12.7 | 26.8 | 33.0 | 36.4 |
Corporate & administrative (AUD Mn) | 1.9 | 3.4 | 5.9 | 4.7 | 6.2 |
Operating income (AUD Mn) | -11.4 | -1.6 | 199.2 | — | — |
Profit before tax (AUD Mn) | -7.8 | 0.18 | 205.1 | 183.0 | 38.9 |
Income tax expense (AUD Mn) | 0 | 0 | 48.1 | 40.9 | 8.5 |
Net profit after tax (AUD Mn) | -7.8 | 0.18 | 157.1 | 142.0 | 30.4 |
Basic EPS (AUD) | — | — | 1.236 | 1.111 | 0.2373 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating margin (%) | -11.0 | 85.9 | — | — |
Pre-tax margin (%) | 1.2 | 88.4 | 80.3 | 45.9 |
Net margin (%) | 1.2 | 67.7 | 62.3 | 35.8 |
R&D as % of revenue (%) | 87.3 | 11.6 | 14.5 | 42.9 |
Effective tax rate (%) | 0 | 23.4 | 22.3 | 21.9 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash & short-term investments (AUD Mn) | 36.8 | 40.2 | 228.5 | 222.2 | 296.1 |
Total assets (AUD Mn) | — | — | — | — | 342.9 |
Total equity (AUD Mn) | — | — | — | — | 338.5 |
Total liabilities (AUD Mn, derived) | — | — | — | — | 4.4 |
Short-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (AUD Mn; negative = net cash) | -36.8 | -40.2 | -228.5 | -222.2 | -296.1 |
Receivables (AUD Mn) | 1.4 | 1.1 | 14.4 | 157.6 | — |
Goodwill & intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | 185.0 | -11.0 | 125.4 |
Capex (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD Mn, derived) | — | — | 185.0 | -11.0 | 125.4 |
Tax paid (AUD Mn) | — | — | — | — | 54.0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 10.4 | 39.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | Basis |
|---|---|---|---|---|
ROE (%) | — | — | 9.0 | NPAT ÷ closing equity (derived) |
ROA (%) | — | — | 8.9 | NPAT ÷ closing total assets (derived) |
ROIC | n/m | n/m | n/m | Invested capital is effectively nil once cash is excluded, so ROIC is not meaningful |
Current ratio | High | High | Above 70x | Liabilities about A$4.4m versus mostly current assets (derived, approximate) |
Debt / equity | 0 | 0 | 0 | No borrowings |
Net debt / EBITDA | Net cash | Net cash | Net cash | FNArena shows Debt/EBITDA of 0 |
Interest coverage | n/m | n/m | n/m | No interest expense |
Asset turnover | — | — | 0.25x | Revenue ÷ closing total assets (derived) |
Cash conversion cycle | n/m | n/m | n/m | No inventory or payables cycle; royalties are received quarterly in arrears |
Revenue by Region and Region Margins & Growth (%)
| Region (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
United States / North America net sales (USD Mn) | 177.2 | 348.4 | 391.4 |
Europe net sales (USD Mn) | 0 | 0 | 0 |
Japan net sales (USD Mn) | 0 | 0 | 0 |
Global DAYBUE net sales (USD Mn) | 177.2 | 348.4 | 391.4 |
YoY growth, global (%) | — | 96.6 | 12.3 |
Revenue by Region
| Region (AUD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
North America royalties (AUD Mn) | 26.8 | 56.2 | 64.6 |
Ex-North America royalties (AUD Mn) | 0 | 0 | 0 |
Revenue by Region (Quarterly)
| Metric | Q1 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
DAYBUE net sales (USD Mn) | 84.6 | 109.6 | 101 | 125 |
Neuren royalty (USD Mn) | — | — | 10.4 | 12.9 |
Share Price History
| Date | Price (AUD) | Context | Source |
|---|---|---|---|
30 Oct 2023 | 10.02 | 52-week low | Kalkine |
28 Dec 2023 | 25.11 | Record high (Kalkine cites A$25.95 intraday) | InvestSMART / Kalkine |
3 Feb 2026 | 14.58 | After negative CHMP trend vote (-10%) | Capital Brief |
27 Feb 2026 | 13.44 | At FY2025 results release | InvestSMART |
Early Apr 2026 | 13.13 | About -30% year to date | Motley Fool |
24 Jul 2026 | 16.46 | Post-CHMP positive opinion | InvestSMART |
26 Aug 2026 | 22.53 then 20.67 | H1 result day (-8%) | InvestSMART |
27 Aug 2026 | 21.02 | — | FNArena |
8 Sep 2026 | 20.64 | Last verified price | Trading Economics |
Share Price & Returns
| Period | Return | Note |
|---|---|---|
1-year (to 8 Sep 2026) | About +2% | Trading Economics. Motley Fool cited a gain of over 25% for the 12 months to 26 Aug 2026; the difference reflects measurement dates around the Sep 2025 peak of about A$20. Both noted. |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | About A$2.61bn | Derived |
Enterprise value | About A$2.32bn | Market cap less A$287m cash (30 Jun 2026) |
Trailing P/E (FY2025 EPS A$0.2373) | About 87x | Derived. StockLight shows about 137x on a trailing-12-month basis. |
Forward P/E (FY2026 consensus EPS 39.8c, FNArena) | About 52x | Derived |
Forward P/E (Bell Potter FY2027 EPS 53.6c) | About 39x | Derived |
EV/Sales (FY2025 revenue A$84.8m) | About 27x | Derived |
EV/Royalty (FY2026 midpoint about A$77.7m) | About 30x | Derived |
P/B (FY2025 equity A$338.5m) | About 7.7x | Derived |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Key forecasts | Date |
|---|---|---|---|---|
Canaccord Genuity | Buy | 24.76 | — | 30 Aug 2026 |
Bell Potter | Positive (top pick lists, Oct 2026) | — | FY2026 DPS 33c, EPS 35.5c; FY2027 DPS 37c, EPS 53.6c | 27 Aug 2026 |
Macquarie | Positive coverage ("could jump more than 50%") | — | — | 2026 |
FNArena consensus | — | 25.00 (about 19% upside at A$21.02) | FY2026 EPS 39.8c | Aug 2026 |
Dividend History
| Period | DPS (AUD) | Franking | Ex-date | Payment | Payout |
|---|---|---|---|---|---|
H1 2026 interim | 0.15 | 100% | 15 Sep 2026 | 7 Oct 2026 | 90% of the A$21.1m Available Pool (A$19.0m) |
H2 2026 final | To be determined | Expected fully franked | — | — | Policy range 70–100% of the H2 Available Pool. The FY2026 pool is estimated at A$48.0–51.6m, implying an H2 pool of about A$27–30m (derived). |
Capital Markets
| Item | Detail |
|---|---|
Buybacks completed | A$10.4m (2024), A$39.6m (2025), A$3.9m (H1 2026) |
Credit ratings (Moody's / S&P / Fitch) | Not rated; no debt |
Debt maturity profile | Not applicable (no borrowings) |
Analyst Conclusions
Management guidance and consensus
FY2026 royalty income: US$53–56m (about A$75–80m at 0.70), up roughly 16–24% on FY2025's A$64.6m in A$ terms.
FY2026 Available Pool: A$48.0–51.6m. This funds the H2 dividend.
Acadia DAYBUE FY2026 net sales: US$480–510m. The 2028 target is US$700m.
Consensus: FY2026 EPS of about 39.8c (FNArena). Bell Potter forecasts EPS of 35.5c (FY2026) and 53.6c (FY2027), and DPS of 33c and 37c.
NNZ-2591: Koala top-line timing to be guided later. PTHS path to be set at the late-Oct 2026 FDA meeting. HIE IND in H1 2027.
Bull case
-
Royalty growth reaccelerating plus new geographies. DAYBUE grew 30% YoY in Q2 2026 on STIX adoption. EU approval and a likely Japan filing add higher-rate royalties of mid-teens to low-20s percent. The pending US$35m EU first-sale milestone and the US$50m North American US$500m milestone (plausible in 2027 given 2026 guidance of US$480–510m) add about US$85m of one-off income.
-
PMS Phase 3 optionality funded without dilution. Neuren holds A$287m of cash against a US$80–90m PMS program budget. A positive Koala result would establish the first approved PMS therapy, in a disease now estimated at 1 in 7,300 people. It would also trigger a fully owned PRV worth about US$215m on recent comps.
-
Unusual capital return profile for a biotech. Fully franked dividends of 70–100% of the Available Pool, plus buybacks, give a valuation floor and broaden the investor base beyond specialist biotech funds.
Bear case
-
The valuation already discounts much of the upside. At about 87x trailing earnings, about 30x EV/FY2026 royalty and 7.7x book, the market implies substantial NNZ-2591 success. A negative Koala outcome would leave a single-product royalty stream with a finite exclusivity horizon (statutory NCE about 2028; orphan exclusivity about 2030).
-
Effect-size and durability questions for trofinetide. The CHMP's initial refusal cited limited treatment effect. EU payers may restrict price and access, and gene therapies in Rett pose a long-term substitution risk.
-
Execution and regulatory friction in the pipeline. FDA's PTHS feedback, the HIE IND delay and no formal Koala top-line guidance suggest timelines could extend. R&D could keep rising (H1 2026 R&D was A$27.4m, up 84%), compressing reported profit and the payout base.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst | Why it matters |
|---|---|---|
| Sep–Nov 2026 | Japan trofinetide top-line results | Gates a 2027 submission, the US$15m first-sale milestone and up to US$110m of sales milestones |
| Early Q4 2026 | Germany launch of DAYBU | US$35m milestone; first EU royalties |
| Late Oct 2026 | FDA Type B meeting (PTHS) | Feasibility and design of a PTHS registrational path |
| Nov 2026 | Acadia Q3 2026 results | Run-rate toward the US$480–510m guidance |
| 13 Nov 2026 | PTHS patient-focused drug development meeting with FDA | Patient-voice evidence base |
| Feb 2027 | FY2026 results and final dividend | Confirms payout ratio and 2027 royalty guidance |
| H1 2027 | HIE IND submission and FDA meeting | Fourth indication |
| 2,027 | Koala enrolment milestones and top-line guidance | Primary value driver |
| 2,027 | Japan regulatory submission | Ex-US expansion |
Analyst verdict
Neuren has completed a rare transition in Australian biotech: from a cash-consuming developer to a profitable, debt-free, dividend-paying royalty company, without raising equity at the point of commercial success. The trofinetide economics are now proven. DAYBUE generated US$391m of net sales in 2025 and is guided to US$480–510m in 2026. Neuren's royalty grew 29% in US$ terms in H1 2026, and the August EU approval opens higher-rate royalties plus a near-term US$35m milestone. The balance sheet of A$287m cash and no debt fully funds a US$80–90m PMS Phase 3 while supporting a payout of 70–100% of royalty-based earnings.
The investment debate has moved from "will trofinetide work commercially?" to "what is NNZ-2591 worth?" At about A$2.6bn market capitalisation and about A$2.3bn enterprise value, the market values Neuren at roughly 30x 2026 royalty income. That multiple only makes sense if a meaningful share of value is attributed to NNZ-2591, the PRV option and the remaining trofinetide milestones. The PMS Phase 3 is therefore the dominant determinant of long-term returns. It has encouraging Phase 2 consistency across three syndromes, FDA alignment on design, and no late-stage competitor. However, the absence of top-line timing guidance and the regulatory friction in PTHS and HIE are reminders that ultra-rare development rarely runs to schedule.
On balance, Neuren is a high-quality, self-funded rare-disease franchise with an asymmetric pipeline option and a growing income floor. Over the next 12 months the key watchpoints are:
-
Japan top-line results;
-
Germany launch execution;
-
the late-October FDA meeting on PTHS;
-
Acadia's progress toward the US$500m North American threshold;
-
any formal guidance on when Koala will read out.
Our stance is constructive with a valuation caveat. Risk/reward looks best on drawdowns linked to sentiment rather than fundamentals, as seen in February–April 2026.
Sources (primary): Neuren ASX announcements: 31 Jan 2024; 24 Apr 2024; 27 May 2024; 9 Aug 2024; 7 Oct 2024; 7 Nov 2024; 28 Feb 2025; 3 Apr 2025 (2024 Annual Report); 27 May 2025; 27 Aug 2025; 3 Feb 2026; 27 Feb 2026 (Appendix 4E and results); 3 Mar 2026; 7 May 2026; 27 May 2026; 5 Aug 2026; 26 Aug 2026 (Appendix 4D and dividend announcement). Acadia Pharmaceuticals Form 8-K exhibits 99.1 (FY2024, Q1 2025, FY2025).
Sources (secondary, flagged where used): FNArena; Motley Fool Australia; InvestSMART; Market Index; Trading Economics; StockLight; FinancialFilings; Biotech Daily; Biotech Dispatch; Capital Brief; Quartr; Kalkine; Yahoo Finance; Barchart; Moomoo; MarketScreener; StockWireX; FilingReader; Angelman.org.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Source |
|---|---|---|---|
Jonathan (Jon) Pilcher | CEO & Managing Director | Long-serving Neuren executive, previously CFO. Succeeded Dr Richard Treagus as CEO after 2020; Managing Director from 14 Jun 2021 per InvestSMART. Morningstar records an association with the company since Aug 2013. | InvestSMART; Morningstar via Motley Fool; FNArena |
Lauren Frazer | CFO & Company Secretary | In role since Aug 2020. Over 25 years' experience in ASX- and Nasdaq-listed companies (business development, capital raising, IR, governance). Has served on boards and the Children's Medical Research Institute IP sub-committee. | Morningstar via Motley Fool |
Gerry (He) Zhao | Chief Business Officer | Previously VP Corporate Development; CBO from about 2024 (MarketScreener: IR contact from 1 Jul 2024). Presented the H1 2026 results. Historical registers show a holding of 405,000 shares (0.32%). | MarketScreener; Quartr; Motley Fool |
Dr Liza Squires | Chief Medical Officer | Leads clinical development of NNZ-2591 | InvestSMART |
Clive Blower | Chief Operations Officer | Operations and manufacturing oversight | InvestSMART |
Daryl Dekarske | Chief Regulatory Officer | Regulatory strategy (FDA, EMA) | InvestSMART |
Dr Larry Glass | Chief Science Officer | Science and preclinical | InvestSMART |
Nancy Jones | VP Clinical Development | Quoted in the PTHS Phase 2 release (May 2024) | ASX 27 May 2024 |
Board of Directors
| Name | Role | Appointed | Background | Independence |
|---|---|---|---|---|
Patrick Davies | Non-Executive Chairman | 1 Jul 2018 | Former CEO of EBOS Group (and previously Symbion). During his ten-year tenure, group enterprise value grew from about A$450m to over A$3.1bn (+20% CAGR). | Independent (non-executive) |
Jon Pilcher | CEO & Managing Director | MD from 14 Jun 2021 | See above | Executive |
Dianne Angus | Non-Executive Director | Jul 2018 | Executive and director experience in biotech, biopharma, medical devices, agritech and healthcare; global industry partnerships | Independent (non-executive) |
Dr Jenny Harry | Non-Executive Director | Jul 2018 | About 20 years in biotech/biopharma executive management; CEO/MD experience from start-up to commercialisation | Independent (non-executive) |
Joseph (Joe) Basile | Non-Executive Director | Mar 2023 | Over 30 years in pharma; former Group CFO of iNova Pharmaceuticals (Singapore); senior finance and commercial roles at Novartis (Australia/Asia) | Independent (non-executive) |
Board & Management Changes
| Date | Change |
|---|---|
Mar 2023 | Joe Basile joined the board |
c.2024 | Gerry Zhao promoted to Chief Business Officer |
2024–2025 | Leadership expanded with Chief Regulatory, Operations and Science officers as Neuren moved "from Phase 2 development to Phase 3 development" (2025 AGM address) |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Milford Asset Management | About 5.14% (largest holder at the time) | FY2023 data (Kalkine, 2024). |
Cameron Richard Pty Ltd | About 3.23% | FY2023 data (Kalkine) |
Top 10 shareholders combined | About 22.7% | FY2023 data (Kalkine) |
Current top-10 holders and substantial holder notices | — | See the 2025 Annual Report shareholder information |
Competitive Landscape
Competitors by Segment
| Indication | Competitor | Asset / modality | Stage (as known) | Positioning vs Neuren |
|---|---|---|---|---|
Rett syndrome | Taysha Gene Therapies | TSHA-102 (AAV9 MECP2 gene therapy) | Pivotal-stage clinical development | Potential one-time therapy; could compete with or complement chronic trofinetide |
Rett syndrome | Neurogene | NGN-401 (gene therapy) | Clinical | Same as above |
Rett syndrome | Anavex Life Sciences | Blarcamesine (sigma-1 agonist) | Mixed clinical results; not approved | Small-molecule alternative; lower probability |
Phelan-McDermid syndrome | Jaguar Gene Therapy | SHANK3 gene therapy (JAG201) | Early clinical | Neuren is materially ahead (only Phase 3 in PMS) |
Angelman syndrome | Ultragenyx | GTX-102 (antisense oligonucleotide, intrathecal) | Phase 3 | Disease-modifying ASO, ahead of NNZ-2591 |
Angelman syndrome | Ionis Pharmaceuticals | ION582 (ASO) | Phase 3 | Same as above |
Angelman syndrome | Roche | Rugonersen (ASO) | Clinical | Big-pharma competitor |
Prader-Willi syndrome | Soleno Therapeutics | DCCR (diazoxide choline, VYKAT XR) | Approved in US (2025) | Established hyperphagia therapy |
Prader-Willi syndrome | Harmony Biosciences; Aardvark Therapeutics | Pitolisant; ARD-101 | Clinical | Crowded field (Neuren cited "other trials available" for PWS families in 2024) |
Fragile X (Acadia-licensed) | Shionogi / Tetra | Zatolmilast (PDE4D inhibitor) | Late clinical | Relevant to Acadia's NNZ-2591 and trofinetide Fragile X options |
Pitt Hopkins syndrome | None identified at late stage | — | — | Neuren cites a lack of competing therapies |
HIE | No approved drug; therapeutic hypothermia is standard of care | — | — | Large unmet need; early stage for Neuren |
Peer Comparison FY2025
| Metric | Neuren (FY2025) | Acadia Pharmaceuticals (FY2025) |
|---|---|---|
Revenue | A$84.8m | US$1.07bn (GAAP) |
Revenue growth | -63% total; +15% royalty | +12% |
Net margin | 35.8% | — |
R&D intensity | 42.9% of revenue | — |
Business model | Royalty plus wholly owned pipeline | Commercial (NUPLAZID, DAYBUE) |



